These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 28762672

  • 1. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D, Tabuchi H, Uno S.
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [Abstract] [Full Text] [Related]

  • 2. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M, Nozawa Y, Kato D, Tabuchi H, Kuroishi K.
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [Abstract] [Full Text] [Related]

  • 3. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y, Kato D, Tabuchi H, Kuroishi K.
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [Abstract] [Full Text] [Related]

  • 4. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
    Kato D, Tabuchi H, Uno S.
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
    [Abstract] [Full Text] [Related]

  • 5. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
    Shen YC, Wang HJ, Chuang YC.
    Int Urol Nephrol; 2018 Jul; 50(7):1219-1226. PubMed ID: 29882001
    [Abstract] [Full Text] [Related]

  • 9. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER.
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [Abstract] [Full Text] [Related]

  • 10. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N, Iuchi H, Kita M, Hashizume K, Matsumoto S, Kakizaki H.
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [Abstract] [Full Text] [Related]

  • 11. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, Drake MJ.
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [Abstract] [Full Text] [Related]

  • 12. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 13. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [Abstract] [Full Text] [Related]

  • 14. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.
    Yamaguchi O, Ikeda Y, Ohkawa S.
    Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
    [Abstract] [Full Text] [Related]

  • 15. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
    Takahashi S, Kato D, Tabuchi H, Uno S.
    Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
    [Abstract] [Full Text] [Related]

  • 16. Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder.
    Liao CH, Kuo HC.
    J Formos Med Assoc; 2019 Mar; 118(3):700-706. PubMed ID: 30172451
    [Abstract] [Full Text] [Related]

  • 17. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
    Shin DG, Kim HW, Yoon SJ, Song SH, Kim YH, Lee YG, Joo KJ, Bae JH, Kang TW, Jeong SJ, Woo SH, Yoo ES, Son H, Koo KC, Kim SW.
    Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, Blauwet MB, Siddiqui E.
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [Abstract] [Full Text] [Related]

  • 19. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K.
    Low Urin Tract Symptoms; 2018 May; 10(2):148-152. PubMed ID: 27911988
    [Abstract] [Full Text] [Related]

  • 20. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
    Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A.
    Drugs Aging; 2020 Sep; 37(9):665-676. PubMed ID: 32725584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.